ClinicalTrials.gg
CompletedNCT02955589Updated Sep 19, 2024Results posted

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

A Phase 2 interventional study of HBI-8000 in Adult T-Cell Lymphoma (ATL), sponsored by HUYABIO International, LLC.. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by HUYABIO International, LLC. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)

Read the detailed description

This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL). HBI 8000 will be administered orally approximately 30 minutes after any regular meal twice a week. There will be 3 to 4 days between dosing. A treatment cycle is defined as 28 consecutive days. HBI-8000 administration will be continued until disease progression or unacceptable toxicities are observed despite appropriate dose reduction or treatment interruption.

02

Conditions studied

  • Adult T-Cell Lymphoma (ATL)
03

In context

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

This study's enrollment of 23 is below the median of 30 across 322 interventional studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

HUYABIO International, LLC. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Histopathological, or cytological diagnosis of ATL confirmed as seropositive for anti-Human T-lymphotrophic Virus type-I (HTLV-I) antibody
  2. Acute, lymphoma or unfavorable chronic types. The unfavorable chronic type is defined by the presence of at least 1 of the following: serum albumin \<3.5 g/dL, lactic dehydrogenase (LDH) >300 U/L, or blood urea nitrogen (BUN) >25 mg/dL. The patient must have at least 1 of , or evaluable lesion in either of peripheral blood or skin
  3. disease after receiving prior systemic therapy with mogamulizumab, or ≥1 prior systemic therapy with cytotoxic chemotherapy in case of intolerance/ for mogamulizumab. And there is no other standard treatment which can be considered appropriate for patients
  4. Male or female, aged 20 years or older
  5. Performance Status of 0-2
  6. of greater than 3 months
  7. Meeting the following baseline laboratory criteria for screening:

    • >1500/µL independent of growth factor support within 7 days
    • >75,000/µL independent of transfusion within 14 days
    • >8 g/dL independent of transfusion within 14 days
    • Serum creatinine \< 1.5 X (ULN)
    • Serum /glutamyl oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamyl pyruvic transaminase (ALT/SGPT) less than or equal to 3 X ULN
    • Serum less than or equal to 1.5 X ULN
  8. Negative serum pregnancy test for females of childbearing (reproductive) potential. Female patients of child bearing potential must use an effective method of (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) during treatment period and 1 month thereafter; Males must use an effective method of birth control (2 barrier methods) during treatment period and 3 months thereafter.

    Note: Female patients will be considered to be women of unless having undergone permanent contraception or . Postmenopausal is defined as at least 12 months without menses with no other medical reasons (e.g., chemical menopause because of treatment with anti-malignant tumor agents).

  9. Signed

Exclusion Criteria:

2.5.2 Exclusion Criteria:

  1. Patients in whom central nervous system lymphoma is recognized during screening (if suspected clinically, imaging study should be performed to confirm)
  2. Male patients with > 450 msec at screening, female patients with QTcF > 470 msec at screening, or patients with congenital long QT syndrome, arrhythmia, history of congestive heart failure ( Class III or IV) or acute myocardial infarction within 6 months of starting the study drug at screening.
  3. Patients with known to benzamide class of compounds or any of the components of HBI-8000 tablets, and patients with prior exposure of HBI-8000;
  4. Patients with a history of second other than disease under study. The exceptions are disease (excluding disease listed below) that has been treated with curative intent with no evidence of recurrence in past 5 years. Furthermore, if the second malignancy is one of the following diseases that were treated with curative intent, it is only required that there is no evidence of recurrence in past 2 years;

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Cervical carcinoma in situ
    • Carcinoma in situ of the breast
    • An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
    • Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
  5. stem cell transplantation within 12 weeks (84 days) of starting the study drug
  6. History of allogeneic stem cell transplantation
  7. Organ transplantation recipients except autologous hematopoietic stem cell transplantation
  8. Uncontrolled inter-current infection
  9. surface antigen-positive, or virus antibody positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen negative, a hepatitis B virus DNA test (real-time PCR measurement) should be performed and if positive, the patient should be excluded from study
  10. Any history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  11. Uncontrolled diabetes mellitus, hypertension, endocrine disorder, bleeding disorder
  12. Major surgery or radiation therapy within 28 days of starting the study drug
  13. Receiving agents or anti-cancer therapy within 28 days, nitrosourea or mitomycin C within 42 days, of starting the study drug
  14. Receiving antibody therapy for ATL within 4 weeks of starting the study drug
  15. Women who are breastfeeding or women who are not willing to stop breastfeeding during study treatment period and for 30 days after the last dose of study drug
  16. Potential for non-compliance or at increased risk based on investigator's judgement
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    HBI-8000

    Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.

    Drug: HBI-8000

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (CR+CRu+PR) was determined based on the response of all compartments (lymph nodes, extranodal masses, spleen \& liver, skin, peripheral blood, and bone marrow) per Tsukasaki criteria and skin lesions were evaluated according to modified SWAT. CR: The disappearance of all disease whereby all criteria met; All compartments are normal. CRu: Lymph nodes ≥75% decrease and extranodal masses ≥75% decrease, but presence of residual lesion; spleen, liver, skin, peripheral blood and bone marrow are normal. PR: Lymph nodes and extradnodal masses - Reduction rate of the sum of 2 dimension products of ≥50% and ≤75%, no increase spleen /liver, skin lesion ≥50% decrease and peripheral blood ≥50% decrease.

    Time frame: Tumor response was assessed until disease progression or unacceptable toxicity, up to 15 months.

Secondary outcomes

  1. Objective Response Rate by Disease Subtype

    Objective response rate (CR+CRu+PR) by disease subtype (acute ATL, lymphoma ATL, unfavorable chronic ATL) was determined based on the response of all compartments (lymph nodes, extranodal masses, spleen \& liver, skin, peripheral blood, and bone marrow) per Tsukasaki criteria and skin lesions were evaluated according to modified SWAT.

    Time frame: Tumor response was assessed until disease progression or unacceptable toxicity, up to 15 months.

  2. Median Duration of Progression-free Survival (PFS)

    PFS was defined as the duration from the date of the first study drug dose to the disease progression or death, whichever occurs first. Evaluation of progression/progressive disease is performed according to the modified criteria of the International Consensus Meeting. Progression is defined as a 50% increase in the sum of 2-dimension products of nodal and/or extra nodal lesions, or 25% increase of mSWAT score in skin lesion, or 50% increase of absolute count of abnormal lymphocyte, or the appearance of new lesions.

    Time frame: From the first day of HBI-8000 dose to the day of disease progression or death, which ever came first, through the end of the study (up to 15 months).

  3. Median Duration of Response (DOR)

    Median duration of response from first response CR, CRu, PR, date to progression, death or last available tumor assessment.

    Time frame: Through the end of the study (up to 12 months).

Other outcomes

  1. Median Duration of Overall Survival (OS)

    Median duration of overall survival is from start of the study to death.

    Time frame: Until death, assessed every 3 months up to 12 months after last treatment through the end of the study (up to 30 months).

  2. Safety and Tolerability, Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

    Safety and tolerability, evaluated as number of participants with treatment-related adverse events as assessed by CTCAE v4.0.

    Time frame: From date of first subject's consent until 30 days after last treatment, assessed up to 25 months.

07

Results

Posted Sep 19, 2024

Participant flow

One more patient than planned consented.

Participant flow — Overall Study
MilestoneHBI-8000
Started23
Completed23
Not completed0

Outcome measures

PrimaryObjective Response Rate

Objective response rate (CR+CRu+PR) was determined based on the response of all compartments (lymph nodes, extranodal masses, spleen \& liver, skin, peripheral blood, and bone marrow) per Tsukasaki criteria and skin lesions were evaluated according to modified SWAT. CR: The disappearance of all disease whereby all criteria met; All compartments are normal. CRu: Lymph nodes ≥75% decrease and extranodal masses ≥75% decrease, but presence of residual lesion; spleen, liver, skin, peripheral blood and bone marrow are normal. PR: Lymph nodes and extradnodal masses - Reduction rate of the sum of 2 dimension products of ≥50% and ≤75%, no increase spleen /liver, skin lesion ≥50% decrease and peripheral blood ≥50% decrease.

Time frame:
Tumor response was assessed until disease progression or unacceptable toxicity, up to 15 months.
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsHBI-8000
Objective Response Rate7
SecondaryObjective Response Rate by Disease Subtype

Objective response rate (CR+CRu+PR) by disease subtype (acute ATL, lymphoma ATL, unfavorable chronic ATL) was determined based on the response of all compartments (lymph nodes, extranodal masses, spleen \& liver, skin, peripheral blood, and bone marrow) per Tsukasaki criteria and skin lesions were evaluated according to modified SWAT.

Time frame:
Tumor response was assessed until disease progression or unacceptable toxicity, up to 15 months.
Reported as:
Count of participants · Participants
Objective Response Rate by Disease Subtype
ParticipantsHBI-8000 Acute ATLHBI-8000 Lymphoma ATLHBI-8000 Unfavorable Chronic ATL
Objective Response Rate by Disease Subtype610
SecondaryMedian Duration of Progression-free Survival (PFS)

PFS was defined as the duration from the date of the first study drug dose to the disease progression or death, whichever occurs first. Evaluation of progression/progressive disease is performed according to the modified criteria of the International Consensus Meeting. Progression is defined as a 50% increase in the sum of 2-dimension products of nodal and/or extra nodal lesions, or 25% increase of mSWAT score in skin lesion, or 50% increase of absolute count of abnormal lymphocyte, or the appearance of new lesions.

Time frame:
From the first day of HBI-8000 dose to the day of disease progression or death, which ever came first, through the end of the study (up to 15 months).
Reported as:
Median · Weeks
Median Duration of Progression-free Survival (PFS)
WeeksHBI-8000
Median Duration of Progression-free Survival (PFS)7.6 (3.4 to 32.1)
SecondaryMedian Duration of Response (DOR)

Median duration of response from first response CR, CRu, PR, date to progression, death or last available tumor assessment.

Time frame:
Through the end of the study (up to 12 months).
Reported as:
Median · Weeks
Median Duration of Response (DOR)
WeeksHBI-8000
Median Duration of Response (DOR)40.0 (11.4 to NA)
Other pre-specifiedMedian Duration of Overall Survival (OS)

Median duration of overall survival is from start of the study to death.

Time frame:
Until death, assessed every 3 months up to 12 months after last treatment through the end of the study (up to 30 months).
Reported as:
Median · Weeks
Median Duration of Overall Survival (OS)
WeeksHBI-8000
Median Duration of Overall Survival (OS)34.4 (10.1 to 78.3)
Other pre-specifiedSafety and Tolerability, Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Safety and tolerability, evaluated as number of participants with treatment-related adverse events as assessed by CTCAE v4.0.

Time frame:
From date of first subject's consent until 30 days after last treatment, assessed up to 25 months.
Reported as:
Count of participants · Participants
Safety and Tolerability, Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
ParticipantsHBI-8000
Safety and Tolerability, Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.023

Adverse events

Collected over From date of the first subject's consent to 12 months after last treatment, assessed up to 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HBI-800016/23 (69.6%)7/23 (30.4%)23/23 (100%)
Most frequent serious events
Most frequent serious events
EventHBI-8000
Platelet count decreasedInvestigations2/23
Urinary Tract InfectionInfections and infestations1/23
Pneumocystis jirovecii pneumoniaInfections and infestations1/23
PalpitationsCardiac disorders1/23
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/23
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/23
Neutrophil count decreasedInvestigations1/23
Most frequent other events
Showing 10 of 21
Most frequent other events
EventHBI-8000
Platelet count decreasedInvestigations15/23
Neutrophil count decreasedInvestigations11/23
White blood cell count decreasedInvestigations9/23
AnaemiaBlood and lymphatic system disorders8/23
Decreased appetiteMetabolism and nutrition disorders8/23
MalaiseGeneral disorders7/23
DiarrhoeaGastrointestinal disorders6/23
Weight decreasedInvestigations4/23
Back painMusculoskeletal and connective tissue disorders4/23
DysgeusiaNervous system disorders4/23

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)HBI-8000
<=18 years0
Between 18 and 65 years1
>=65 years22
Age, Continuous
Age, Continuous(Years)HBI-8000
Mean73.4 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)HBI-8000
Female8
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HBI-8000
American Indian or Alaska Native0
Asian23
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)HBI-8000
Japan23
Sub-Type of ATL at Screening
Sub-Type of ATL at Screening(Participants)HBI-8000
Acute ATL13
Lymphoma ATL8
Unfavorable Chronic ATL2
08

Study locations

15 sites
  • Fukuoka, Japan
  • Isehara, Japan
  • Kagoshima, Japan
  • Miyagi, Japan
  • Miyazaki, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Oita, Japan
  • Okinawa, Japan
  • Omura, Japan
  • Saitama, Japan
  • Sapporo, Japan
  • Suita, Japan
  • Tokyo, Japan
  • Yufu, Japan
09

References and documents

Publications

  • Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results. Cancer Sci. 2022 Aug;113(8):2778-2787. doi: 10.1111/cas.15431. Epub 2022 Jun 7. PubMed 35579212 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Dec 2018 and a completion of Nov 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2024, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 4, 2016
Start
Nov 2016
Primary completionActual
Dec 2018
CompletionActual
Nov 2019
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02955589
Lead sponsor
HUYABIO International, LLC.
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Nov 2016
Primary completion
Dec 2018
Completion
Nov 2019
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Gloria Lee, MD
study chair · HUYA Bioscience International, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion